We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cara Therapeutics Inc | NASDAQ:CARA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0162 | 2.15% | 0.77 | 0.725 | 0.84 | 0.8094 | 0.75 | 0.76 | 255,069 | 01:00:00 |
|
Delaware
(State or other jurisdiction of incorporation or organization |
| |
75-3175693
(I. R. S. Employer Identification No.) |
|
|
4 Stamford Plaza
107 Elm Street, 9th Floor Stamford, Connecticut 06902 (203) 406-3700 |
|
|
Christopher Posner
Chief Executive Officer Cara Therapeutics, Inc. 4 Stamford Plaza 107 Elm Street, Ninth Floor Stamford, Connecticut 06902 (203) 406-3700 |
|
|
Copies to:
Darren DeStefano Nicolas H.R. Dumont Cooley LLP 11951 Freedom Drive, 14th Floor Reston, VA 20190-5640 (703) 456-8000 |
|
|
From time to time after the effective date of this Registration Statement
(Approximate date of commencement of proposed sale to the public)
|
|
|
Large accelerated filer
☒
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☐
|
| |
Smaller reporting company
☐
|
|
| | | |
Emerging Growth Company
☐
|
|
|
SEC registration fee
|
| | | $ | 27,810 | | |
|
Accounting fees and expenses
|
| | | | * | | |
|
Legal fees and expenses
|
| | | | * | | |
|
Transfer agent fees and expenses
|
| | | | * | | |
|
Trustee fees and expenses
|
| | | | * | | |
|
Printing and miscellaneous expenses
|
| | | | * | | |
|
Total
|
| | | $ | * | | |
Exhibit
Number |
| |
Description of Document
|
| |||
| | 1.1(1) | | | | Form of Underwriting Agreement | |
| | 1.2(6) | | | | | |
| | 3.1(2) | | | | | |
| | 3.2(3) | | | | | |
| | 4.1(4) | | | | | |
| | 4.2(6) | | | | | |
| | 4.3(1) | | | | Form of Note | |
| | 4.4(6) | | | | | |
| | 4.5(6) | | | | | |
| | 4.6(6) | | | | | |
| | 4.7(1) | | | | Form of Specimen Preferred Stock Certificate and Certificate of Designations of Preferred Stock | |
| | 4.8(5) | | | | | |
| | 5.1(6) | | | | | |
| | 23.1 | | | | | |
| | 23.2(6) | | | | | |
| | 24.1(6) | | | | | |
| | 25.1(1) | | | | Statement of Eligibility of Trustee under the Debt Indenture | |
| | 107(6) | | | | |
| | | | CARA THERAPEUTICS, INC. | | |||
| | | | By: | | |
/s/ CHRISTOPHER POSNER
Christopher Posner
Chief Executive Officer |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
*
Christopher Posner
|
| | President, Chief Executive Officer and Director(Principal Executive Officer) | | | May 9, 2022 | |
|
*
Thomas Reilly
|
| | Chief Financial Officer(Principal Financial and Accounting Officer) | | | May 9, 2022 | |
|
*
Martin Vogelbaum
|
| | Director | | | May 9, 2022 | |
|
*
Harrison M. Bains, Jr.
|
| | Director | | | May 9, 2022 | |
|
*
Jeffrey Ives, Ph.D.
|
| | Director | | | May 9, 2022 | |
|
*
Susan Shiff
|
| | Director | | | May 9, 2022 | |
|
* By: /s/ Thomas Reilly
Thomas Reilly, Attorney-in-Fact
|
| | | | | | |
1 Year Cara Therapeutics Chart |
1 Month Cara Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions